Skip to main content

ACE your high blood pressure test with wine

94. Resveratrol gets all the attention but it is far from the only healthy thing in wine (in fact it is a relatively minor component.) Another class of compounds call oligomeric proanthocyanidins (let's just call them OPC's) have a unique mechanism for lowering blood pressure. Researchers at the University of Buenos Aires found that they inhibit an enzyme called Angiotensin Converting Enzyme which contributes to hypertension in many people. Prescription ACE inhibitors are available as well, but who wouldn't rather drink a glass of red wine? It does have to be red, and it does have to be wine, because OPC's come almost exclusively from the seeds and alcoholic fermentation is required for extraction.

Comments

Popular posts from this blog

Which came first: Beer or wine? (or something else?)

Actually neither beer nor wine was the first fermented beverage, and wine arguably has a closer connection to health, but recent evidence indicates that humans developed the ability to metabolize alcohol long before we were even human. The uniquely human ability to handle alcohol comes from the digestive enzyme alcohol dehydrogenase, or ADH4. A new science called paleogenetics identifies the emergence of the modern version of the ADH4 gene in our ape ancestors some 10 million years ago. Interestingly, this corresponds to the time when our arboreal forebears transitioned to a nomadic lifestyle on the ground. We went from swinging from tree limbs to walking upright, and the rest is history. Understanding the circumstances that led to perpetuation of the ADH4 mutation may contain clues to what made us human in the first place. How the ability to metabolize alcohol made us human Paleogenetecist Matthew Carrigan has an idea about how this happened . Arboreal species rely on fruit tha

Why I am not surprised that the NIH cancelled the alcohol-health study

Not long after enrolling the first patients in the much hyped prospective study on alcohol and health, the National Institutes of Health recently announced that they were pulling the plug. I am actually more surprised that they ever got it off the ground in the first place. As I wrote a year ago when the study was still in its planning stages, there were too many competing interests, criticisms of the study design, and concerns about funding to expect that whatever results came out would be universally accepted. Nevertheless, I am disappointed. The study, called Moderate Alcohol and Cardiovascular Health Trial (MACH) was intended to provide hard evidence about the health effects of moderate alcohol consumption by prospectively assigning subjects with heart disease to one drink per day or not drinking, which they were to follow for up to 10 years. Most existing data on the question is retrospective, or simply tracks a subject population according to their drinking preferences, w